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Abstract
Background: cDNA microarrays are a powerful means to screen for biologically relevant gene
expression changes, but are often limited by their ability to detect small changes accurately due to
"noise" from random and systematic errors. While experimental designs and statistical analysis
methods have been proposed to reduce these errors, few studies have tested their accuracy and
ability to identify small, but biologically important, changes. Here, we have compared two cDNA
microarray experimental design methods with northern blot confirmation to reveal changes in gene
expression that could contribute to the early antiproliferative effects of neuregulin on MCF10AT
human breast epithelial cells.
Results: We performed parallel experiments on identical samples using a dye-swap design with
ANOVA and an experimental design that excludes systematic biases by "correcting" experimental/
control hybridization ratios with control/control hybridizations on a spot-by-spot basis. We refer
to this approach as the "control correction method" (CCM). Using replicate arrays, we identified
a decrease in proliferation genes and an increase in differentiation genes. Using an arbitrary cut-off
of 1.7-fold and p values <0.05, we identified a total of 32 differentially expressed genes, 9 with the
dye-swap method, 18 with the CCM, and 5 genes with both methods. 23 of these 32 genes were
subsequently verified by northern blotting. Most of these were <2-fold changes. While the dye-
swap method (using either ANOVA or Bayesian analysis) detected a smaller number of genes (14–
16) compared to the CCM (46), it was more accurate (89–92% vs. 75%). Compared to the
northern blot results, for most genes, the microarray results underestimated the fold change,
implicating the importance of detecting these small changes.
Conclusions: We validated two experimental design paradigms for cDNA microarray
experiments capable of detecting small (<2-fold) changes in gene expression with excellent fidelity
that revealed potentially important genes associated with the anti-proliferative effects of neuregulin
on MCF10AT breast epithelial cells.
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Background
Spotted cDNA microarrays are used in high-throughput
experiments that interrogate the relative expression of
thousands of genes simultaneously for many biological
processes with wide applications in biological and medi-
cal research. Typically in a two-dye spotted cDNA micro-
array experiment, two mRNA samples are transcribed into
cDNAs, labeled with two different fluorescent dyes, com-
monly Cy3 and Cy5, and hybridized on the same slide.
The relative gene expression level is then measured as a
ratio of the intensities of the fluorescent dyes. However,
the signal intensity of the dye, which indirectly represents
the gene expression level, can be affected by many other
sources of error such as dye efficiency, sample prepara-
tion, and the variability of the biological samples [1,2].
An important question is how to identify differentially
expressed genes, some of which change only minimally
(<2-fold), given many known and potentially unknown
sources of variance in the microarray experiment. In order
to reduce false positive rates, many published experiments
use a cut-off of 2- to 3-fold [3-5]. This limits the ability of
the microarray experiment to detect small, but biologi-
cally important changes. In fact, recent reports have
shown that microarrays can significantly underestimate
gene expression changes and therefore a high cut-off will
miss important changes [6]. Although more sophisticated
statistical methods have been proposed for single slide
analysis [7-13], it is becoming clear that in order to reduce
random variance, replication becomes more and more
important in microarray experimental design by greatly
increasing the power of the experiment to measure small
gene expression changes [2,13-17]. As a relatively new
technique, many new theories have been developed for
data analysis and experimental design, but few of these
theories have been rigorously tested against a well-estab-
lished standard method such as the Northern blot.
In this paper we compared two experimental design and
analysis methods performed on quadruplicate arrays that
include a dye-swap design [18,19] and a modified refer-
ence design method that uses a control-control hybridiza-
tion to correct for systematic experimental errors, that we
refer to as the "control correction method" (CCM). We
demonstrate that both experimental designs accurately
identified small (<2-fold) gene expression changes after a
24-hour treatment of MCF10AT breast epithelial cells
with the growth and differentiation factor neuregulin.
These changes correlate well with the anti-proliferative
effects of neuregulin resulting in a relative decrease in pro-
liferative genes and increase in anti-proliferative genes
that will be important for future investigations.
Results
The results presented in this paper demonstrate two, com-
plementary cDNA microarray methods capable of reliably
revealing small changes in gene expression in transformed
human breast epithelial MCF10AT cells after treatment
with neuregulin. Since, as shown in Fig. 1, treatment of
these cells with neuregulin significantly slows their
growth rate, identifying early gene expression changes in
this process will be important in understanding how neu-
regulin regulates cell growth in both normal and malig-
nant breast epithelium, and will also provide both
biological markers and potential targets in breast cancer.
Large quantities of highly purified total RNA were isolated
from MCF10AT cells treated with or without neuregulin
for 24 hours and used both for microarray experiments
and northern blot confirmation studies.
Anti-proliferative effects of neuregulin on MCF10AT cellsFigure 1
Anti-proliferative effects of neuregulin on MCF10AT cells. 
Quadruplicate cultures of MCF10AT cells were treated with 
and without 1 nM neuregulin 3 days after plating and cell 
counts were performed demonstrating a significant decrease 
in their growth 24 and 48 hours after treatment. The p value 
for 24 hr was 0.0011, and for 48 hr was 1.46E-05.
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Experimental designs to address systematic errors
As with most experimental methods, replicate measure-
ments can reduce random errors. Equally important are
systematic errors. Systematic errors result from a constant
tendency to over- and under-estimate true values and can-
not be eliminated by replicate analysis, since they are
often highly reproducible. An example of such a system-
atic error is a gene-specific dye effect, also called "dye–
gene" interaction [18], and is shown in Fig. 2A. For a given
gene spotted in duplicate (arrows), the red signal labeling
the treated sample (T) is much brighter than the green sig-
nal for the control sample (C). This was highly reproduc-
ible for both spots on the same array and between
multiple arrays. One way to determine whether the appar-
ent up-regulation of this gene is true, is to use the same
control sample labeled with both red and green dyes and
perform a control/control (C/C) hybridization. Fig. 2A
shows that the same intense red signal is seen in the C/C
hybridization as was seen in the treated/control (T/C),
demonstrating that this signal is a systematic error pro-
ducing a false positive gene expression change.
Given the unavoidable presence of these systematic errors,
methods to correct these errors are needed. One way to
correct for systematic errors in microarray experiments is
to take advantage of C/C hybridizations to correct the T/C
hybridizations. This requires a modified reference design,
which we refer to as a "control correction" design. This is
different from a common reference design used previ-
ously [19,20]. Here, each spot of the T/C hybridization is
"corrected" by the same spot from the C/C hybridization
for systematic errors. A second method that will also cor-
rect for systematic errors is a "dye-swap" design
[16,17,19]. The dye-swap design uses an ANOVA to calcu-
late gene expression changes from replicate cDNA micro-
arrays probed with T/C hybridizations performed where
the dye color is swapped. Included in the ANOVA are fac-
tors to correct for systematic errors such as dye and dye-
gene interactions. The "control correction" and the dye-
swap designs are compared in Fig. 2B. Each of these exper-
imental designs was performed on quadruplicate arrays.
Each of these two designs required its own analysis
method. While we used an analysis method that utilizes
individual t-tests for each spot for the CCM, we compared
both ANOVA and Bayesian analysis methods for the dye-
swap design.
Control correction method experimental design and 
results
A flow chart for the control correction method is shown in
Fig. 2C. All microarrays used in this study were from the
same lot of 3333 gene spotted cDNA slides (similar to the
commercially available NEN MicroMax 2400 slides with
933 additional genes (Alphagene Inc., Woburn, MA)
where each gene was spotted in duplicate, and hybridized
using an optimized, two-step hybridization protocol with
either Cy3 or Cy5-labeled dendrimer complexes (Geni-
sphere, Hatfield, PA). A key advantage of the Genisphere
Dendrimer system is the need for only 3 µg of total RNA
per array without the need for a potentially non-linear
amplification step to boost the signal. After scanning and
spot-wise local background correction (Imagene Software,
Biodiscovery, CA), a log Cy5/Cy3 ratio versus log signal
intensity MA plot was prepared and shown in Fig 3A[20].
Without any correction, the ratio vs. intensity plot shows
a banana shape as ratios trend downward in the low
intensity range. This suggests an intensity-dependent dye
effect. In order to correct this and to normalize data sets
between different slides, an intensity-dependent normali-
zation procedure was performed that fits the data to a low-
ess curve as a function of signal intensity [21]. After
normalization, the log ratios became more evenly distrib-
uted around zero (Fig. 3B).
However, despite this relatively even distribution, histo-
grams of normalized log ratios for T/C and C/C display
long tails to the left as shown in the histograms in Fig. 4A
and the quantile-qauntile plots in Fig. 4B. Since there
should be no treatment effects on the C/C slides, a sym-
metric, normal distribution would have been expected.
The skewed appearances of the normalized distributions
indicate additional, uncorrected systematic errors in both
T/C and C/C hybridizations. "Correction" of each spot by
subtracting the log (C/C) ratios from the log (T/C) ratios
produces an approximately normal distribution of the log
(T/C) ratios (shown on the bottom of Figs. 4A and 4B). In
addition to the systematic errors that occur on a spot-by-
spot basis shown in Fig. 2A, systematic errors were found
as a function of slide location, particularly at the edge of
the arrays. These errors were also corrected by this method
(data not shown). Yang and Dudoit proposed a within
slide normalization for this type of spatial effect [21],
however, one concern for within slide normalization is
that if the number of genes is small in each spatial group,
the assumption that there will be an equal proportion of
up- and down-regulated genes may be untrue.
As a final step, a t-test was performed to compare the nor-
malized log ratios of T/C and C/C for each gene. This
yields p values for each control-corrected fold change cal-
culated as log (T/C)-log (C/C). In Fig. 5, the average and
standard deviation of gene expression ratios for the log (T/
C) and log (C/C) are plotted for the genes using 1.7-fold
and p < 0.05 cut-offs. This clearly demonstrates the impor-
tance of correcting each log (T/C) value with the corre-
sponding log (C/C) control value. For example, while
some log (T/C) ratios are close to zero, by using the log
(C/C) as baseline, true gene expression changes above or
below this were identified that would otherwise have
been missed. The 1.7-fold cutoff was chosen to be within
BMC Bioinformatics 2004, 5:99 http://www.biomedcentral.com/1471-2105/5/99
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(A) Highly reproducible systematic errors from gene-dye interactionsFigure 2
(A) Highly reproducible systematic errors from gene-dye interactions. The arrows demonstrate intense red dye labeling for a 
given gene spotted in duplicate both for the T/C slide where the treated sample is labeled with red dye (Cy5) and control sam-
ple is labeled with green dye (Cy3), as well as in the C/C slide where the same sample is labeled both red and green. (B) Exper-
imental designs. Two different experimental methods were compared: A dye-swap approach, where the dye color is reversed 
for T/C hybridizations, and a "control correction" design, where T/C and C/C hybridizations are performed without reversing 
the dyes. T denotes the neuregulin treated cells, while C denotes the untreated, control cells. Each arrows represent a repli-
cate and the tails of the arrows indicate cy5 labeling and the heads indicate cy3 labeling. (C) Data processing flow chart for the 
control correction method.
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the detection range of northern blot analyses, which we
felt would be the most sensitive method to confirm these
small changes. A volcano plot, shown in Fig. 6A, summa-
ries 46 differentially-regulated genes that met these crite-
ria for the CCM.
Comparison of the control correction to the dye-swap 
design
Many have proposed that a dye-swap experimental design
combined with an ANOVA will correct for systematic
errors [17-19]. To verify this and compare the dye-swap
design to the control correction design, a dye-swap exper-
iment was performed on quadruplicate arrays using the
same RNA samples and the two interconnect ANOVA
model of Wolfinger et al [22,23]. Using this experimental
design with the same cut-off values, 14 differentially
expressed genes were identified and are presented as a vol-
cano plot alongside that of the CCM (Fig. 6B).
Table 1 lists those genes that met our selection criteria,
together with their fold-change, p values, and functional
classifications. Only 5 genes were found in common for
both methods. The genes have been broadly grouped into
proliferation, differentiation, and unclassified genes in
order to observe trends in the neuregulin-induced gene
expression changes that could be important in regulating
cell growth. A general trend showing a down-regulation of
proliferation genes and up-regulation of differentiation
genes was observed. This includes several oncogenes, cell
cycle control and cell proliferation genes that were all
down-regulated; and tumor suppressor genes, growth
inhibition and differentiation genes were up-regulated.
This pattern is consistent with the anti-proliferative/differ-
entiation effects of neuregulin on MCF10AT human
breast epithelial cells.
Verification of microarray accuracy by northern blot 
analysis
To confirm these gene expression changes and to deter-
mine the accuracy of each experimental method, we
selected 23 genes for verification by northern blot. We
chose all 5 genes detected by both methods, 6 up-regu-
lated and 5 down-regulated genes from the control correc-
tion design, and 7 genes from the dye-swap experiment.
The selection of genes was not random, as we selected a
balanced complement of genes of variable intensity that
were both up- and down-regulated. The probes used for
northern blots were generated by PCR from clones used to
spot the arrays. Each blot contained triplicate control and
treated samples and was re-probed multiple times. Fig. 7
summarizes the northern blot results for these 23 genes.
The band intensities were quantified, normalized to total
ribosomal RNA for each gel, and averaged to produce a
fold change that was compared directly to the fold change
from the microarrays. In general, differential gene expres-
sion was confirmed by the northern blots for both array
design methods. For the dye-swap method only 1 of 12
genes was a false positive, while 4 out of 16 genes were
false positives in the control correction method. Down-
regulated genes were verified more reliably in the control
correction method (10/10) than up-regulated genes (2/6).
All differentially expressed genes common to both meth-
ods were confirmed..
Since the ANOVA method we used can sometimes under-
estimate the variance, we re-analyzed our dye-swap data
Array and intensity-dependent variation can be corrected by no malizat on based on i tensityFigure 3
Array and intensity-dependent variation can be corrected by 
normalization based on intensity. (A) This is an MA-plot 
before normalization for one of T/C slides that plots the log 
intensity ratios against the averaged intensities at both wave-
lengths: M = log (T/C) and A = 1/2log(T*C). The majority of 
the data is less than zero in a "banana" or "comma" shaped 
distribution. This demonstrates a systematic, intensity-
dependent dye effect, prominent at lower intensities. (B) 
After normalization using the lowess function, the MA-plot 
shows a more even distribution at all intensities.
BMC Bioinformatics 2004, 5:99 http://www.biomedcentral.com/1471-2105/5/99
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with a Bayesian method using a regularized t-test as
implemented in Cyber-T [24]. This analysis revealed 16
differentially expressed genes using the same cut-offs, 10
of which were in common with the ANOVA method
(Table 1). A greater number of genes were identified using
the regularized t-test, and the corresponding p values for
these genes were lower. Based on the previous northern
blot data, 8/9 (89%) of these were confirmed.
Control correction of each spot markedly improves the distribution of log ratiosFigu e 4
Control correction of each spot markedly improves the distribution of log ratios. (A) Histograms show that T/C and C/C log 
ratio distributions after lowess normalization still have a marked asymmetry with a larger tail towards the left (increased down-
regulated genes). The distribution becomes symmetric after subtracting the log (C/C) from the log (T/C). (B) Quantile-quantile 
plots similarly show that the log ratio distribution becomes more normal after correction of each spot with the control ratio.
BMC Bioinformatics 2004, 5:99 http://www.biomedcentral.com/1471-2105/5/99
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Discussion
Gene expression changes in MCF10AT cells suggest a rapid 
anti-proliferative effect of neuregulin
MCF10AT cells are a human breast epithelial cell line sta-
bly transfected with a mutant ras oncogene. These cells are
pre-malignant, but can progress to invasive carcinoma
[25,26]. Given that neuregulin can differentially affect the
growth properties of different cell lines, we used the
MCF10AT cell line as model system to identify genes that
may be down-stream from neuregulin activation and
could thus be studied further for their roles in breast can-
cer cells that respond differentially to neuregulin. Com-
bining two cDNA microarray experimental design
methods, we have identified genes differentially expressed
by neuregulin treatment that correlated with a significant
decrease in their growth rate. The pattern of expression
clearly shows an anti-proliferative effect of neuregulin on
the MCF10AT cells with a reduction in genes associated
with proliferation such as heat shock proteins, oncogenes,
cell cycle control genes, genes involved in fatty acid and
sugar synthesis, transcription and translation together
with an increase in differentiation genes including tumor
suppressor genes, DNA damage repair genes, growth inhi-
bition genes and differentiation genes. We further showed
The control correction method identifies gene expression changes from spots with variable C/C ratiosFigure 5
The control correction method identifies gene expression changes from spots with variable C/C ratios. The log ratios for each 
gene are plotted both for the T/C () and the corresponding C/C (▲) hybridizations for the 46 genes selected from control 
correction method. The error bars represent one standard deviation in each direction.
BMC Bioinformatics 2004, 5:99 http://www.biomedcentral.com/1471-2105/5/99
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that these effects are biologically consistent with the rapid,
anti-proliferative effects of neuregulin on cell number.
Additional experiments have shown that these genes are
important biological markers for the degree of malig-
nancy in other breast epithelial cell lines that have differ-
ential proliferation responses to neuregulin (Li Q, Ahmed
S, and Loeb JA, unpublished results).
Both experimental designs demonstrate a high 
confirmation rate for small changes in gene expression
One of the important tasks in microarray technology is to
design experiments and develop statistical tools to obtain
data efficiently and accurately to answer fundamental
questions in biology. In many experiments, this requires
the ability to detect small changes in gene expression with
high fidelity. In this study we compared two common
experimental design paradigms for cDNA microarrays and
determined their accuracy by northern blot. Both
methods identified small expression changes with consid-
erable accuracy. In the control correction design, we used
control hybridizations to correct for systematic errors on a
spot-by-spot basis. The method is based on an assump-
tion that systematic errors from slides made from the
same lot and processed identically do not vary signifi-
cantly. To minimize the possible variance of systematic
errors in T/C slides and C/C slides we maintained strict
experimental conditions, such as same-day sample prepa-
ration and same-day hybridization. We also used the
same control samples for both the T/C and C/C hybridi-
zations instead of using an arbitrary control sample that
might be quite different in mRNA composition [19]. This
results in similar spot intensities for each gene both in the
treatment and the control and will minimize any differ-
ences that could be caused by the different mRNA compo-
sitions from different samples. This spot-by-spot control
correction can eliminate systematic errors that cannot be
corrected with slide-wise normalization. Similarly, in the
dye-swap design, two different dyes are used to label the
same sample, which enables the correction of dye-gene
interactions in the ANOVA model.
A summary of the results from this study are shown in the
Venn diagrams in Fig. 8. Using the 1.7-fold and p < 0.05
cut-offs, the overall verification rate was 75% for the CCM
and 92% for the dye-swap method using ANOVA. Among
the 18 confirmed expression changes, all were below 3-
fold and only six were above 2-fold. Many of the expres-
sion changes below 2-fold on the microarrays
underestimated the fold-change measured by northern
blotting. The accuracy was not dependent on microarray
spot intensity as genes with both low and high signal
intensities had similar verification rates (data not shown).
The confirmation rates for both methods are comparable
to methods reported by Mutch (87.5%) [27] and Tusher
(92%) [28]. Of particular importance in this study is our
high confirmation rates for genes differentially expressed
by 2-fold or less.
The t-test used for the CCM and ANOVA for the dye-swap
method depend on assumptions of Gaussian
Both control correction and dye-swap methods reveal statis-tically significant changes i  gen  expressionFigure 6
Both control correction and dye-swap methods reveal statis-
tically significant changes in gene expression. Volcano plots of 
the control correction method (A) and the dye-swap 
method (B) reveal a small proportion of genes that met our 
arbitrary criteria of having >1.7 fold changes with p values 
<0.05, determined individually for each gene. The horizontal 
lines on each graph represent p = 0.05. The vertical lines rep-
resent 1.7 fold changes, both up- and down-regulated. Genes 
shown in blue in upper left and right areas were selected for 
northern blot confirmation.
BMC Bioinformatics 2004, 5:99 http://www.biomedcentral.com/1471-2105/5/99
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Table 1: List of identified genes. Gene accession numbers, gene descriptions, fold-changes, and p-values for genes identified by the dye-
swap method with ANOVA and regularized t-test analysis and the control correction method (CCM). Genes are broadly classified into 
three groups: proliferation-related, differentiation-related and unclassified.
Proliferation-Related Genes
Classification Acc# Gene Description CCM 
fold
CCM 
p-value
Dye-Swap 
fold
Dye-Swap 
p-value
Regularized 
fold
Regularized 
p-value
Heat shock 
proteins
NM_006597 heat shock 70 kDa protein 8 -2.8 9.5E-6 -2.9 4.2E-7 -2.9 8.4E-13
M34664 heat shock 60 kDa protein 1 
(chaperonin)
-1.9 3.9E-6 -1.9 4.8E-10
L15189 heat shock 70 kDa protein 9B 
(mortalin-2)
-2.2 1.4E-3 -1.8 1.8E-6 -1.8 6.5E-6
M22382 Human mitochondrial matrix 
protein P1
-1.8 1.5E-5 -1.7 2.9E-9
M94859 Human calnexin mRNA, 
complete cds
-1.8 4.1E-3
L27706 Human chaperonin protein 
(Tcp20) gene complete cds
-2.1 3.8E-4
Transcription 
and 
translation
D29677 helicase with zinc finger 
domain
-1.9 3.1E-5 -1.9 2.8E-10
X91257 seryl-tRNA synthetase -1.8 1.2E-3 -1.8 4.5E-8 -1.9 2.0E-11
D30655 eukaryotic translation 
initiation factor 4A, isoform 2
-1.7 5.5E-5
U76111 Human translation repressor 
NAT1 mRNA, complete cds
-1.7 8.9E-3
M74719 transcription factor 4 -1.9 2.0E-3
X13293 Human mRNA for B-myb 
gene
1.7 4.2E-9
U00968 Human SREBP-1 mRNA -1.7 8.4E-9
L41490 eukaryotic translation 
elongation factor 1 alpha 1-
like 14
-1.8 1.4E-5 -1.7 5.3E-5 -1.8 5.0E-12
Fatty acid and 
sugar 
metabolism
D16481 Homo sapiens mRNA for 
mitochondrial 3-ketoacyl-CoA 
thiolase beta-subunit of 
trifunctional protein, complete 
cds
-1.8 5.6E-5
Y00711 Human mRNA for lactate 
dehydrogenase B (LDH-B)
-1.8 6.9E-5 -1.7 2.4E-8
D78130 Homo sapiens mRNA for 
squalene epoxidase, complete 
cds
-1.9 1.2E-5 -1.8 9.5E-7
M37154 Human glutamate 
dehydrogenase (GDH) 
mRNA, complete cds
-1.8 4.0E-3 -1.7 8.0E-4
U62961 3-oxoacid CoA transferase -2.0 1.2E-4
Y13647 Homo sapiens mRNA for 
stearoyl-CoA desaturase
-1.9 1.5E-6
GTPase Y13286 Homo sapiens mRNA for 
GDP dissociation inhibitor 
beta
-1.8 1.8E-5 -1.7 1.3E-6
X51408 Human mRNA for n-
chimaerin
2.1 1.8E-2
Cell cycle U47413 Human cyclin G1 mRNA, 
complete cds
-1.7 9.6E-7
AF139897 Homo sapiens BASS1 (BASS1) 
mRNA, partial cds
-1.8 1.8E-3
D00265 Homo sapiens mRNA for 
cytochrome c, partial cds
-2.0 2.0E-2
X68836 H. sapiens mRNA for S-
adenosylmethionine 
synthetase
-2.2 8.3E-6
BMC Bioinformatics 2004, 5:99 http://www.biomedcentral.com/1471-2105/5/99
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U19251 Homo sapiens neuronal 
apoptosis inhibitory protein 
mRNA, complete cds
1.8 1.1E-2
S45630 alpha B-crystallin=Rosenthal 
fiber component [human, 
glioma cell line, mRNA, 691 
nt]
2.1 2.7E-3
X86779 H. sapiens mRNA for FAST 
kinase
1.7 1.9E-2
Oncogenes X03541 Human mRNA of trk 
oncogene
-1.8 3.1E-3
M19722 Human fgr proto-oncogene 
encoded p55-c-fgr protein, 
complete cds
-1.9 5.0E-3
X77548 H. sapiens cDNA for RFG -2.1 1.5E-3
Proliferation D63390 platelet-activating factor 
acetylhydrolase, isoform Ib, 
beta subunit 30 kDa
-1.8 4.4E-4
U62739 Human branched-chain amino 
acid aminotransferase 
(ECA40) mRNA, complete 
cds
1.7 1.2E-2
L12350 Human thrombospondin 2 
(THBS2) mRNA, complete 
cds
1.9 2.2E-3
X06614 Human mRNA for receptor of 
retinoic acid
1.7 2.8E-2
Y07921 Human mRNA for serine 
protease
-1.7 1.1E-6
Differentiation-Related Genes
Tumor 
suppressor
AF042857 Homo sapiens lung cancer 
antigen NY-LU-12 variant A 
mRNA, complete cds
2.1 4.4E-3
Differentiation M21300 Human small proline rich 
protein (sprI) mRNA, clone 
15B
1.7 2.0E-4
ECM and 
vesicle 
trafficking
M15395 Human leukocyte adhesion 
protein (LFA-1/Mac-1/p150,95 
family) beta subunit mRNA
2.0 2.8E-2
S72869 H4(D10S170) = putative 
cytoskeletal protein [human, 
thyroid, mRNA, 3011 nt]
-1.9 3.2E-2
D21267 SNAP25 synaptosomal-
associated protein, 25 kDa
1.9 1.7E-2
U95735 Human thrombospondin 2 
(THBS2) mRNA, complete 
cds
-1.8 1.5E-5
X68194 H. sapiens h-Sp1 mRNA -1.7 4.2E-2
Z74615 collagen, type I, alpha 1 2.5 5.3E-3
Immune-
response
U68030 chemokine (C-C motif) 
receptor 6
1.8 5.8E-3
X04701 Human mRNA for 
complement component C1r
-2.4 3.3E-2
DNA repair D79983 ring finger protein 144 1.7 2.3E-2
D29013 Homo sapiens mRNA for 
DNA polymerase beta, 
complete cds
1.8 7.3E-3
Unclassified Genes
J02854 myosin, light polypeptide 9, 
regulatory
2.6 4.5E-2
Table 1: List of identified genes. Gene accession numbers, gene descriptions, fold-changes, and p-values for genes identified by the dye-
swap method with ANOVA and regularized t-test analysis and the control correction method (CCM). Genes are broadly classified into 
three groups: proliferation-related, differentiation-related and unclassified. (Continued)
BMC Bioinformatics 2004, 5:99 http://www.biomedcentral.com/1471-2105/5/99
Page 11 of 16
(page number not for citation purposes)
distributions that may or may not be present in a micro-
array experiment with a small number of replicates. Some
efforts have been made to develop Bayesian frameworks
that incorporate prior distributions in order to estimate
the noise [24,29,30]. We therefore re-analyzed our dye-
swap data using a "regularized" t-test [24]. Using this, we
identified 16 genes that met our cut-off criteria, 10 of
which were in common with the ANOVA analysis. Of
those genes that we measured by northern blot analysis,
8/9 or 89% were verified. In summary, the regularized t-
test revealed more genes than the ANOVA method with
generally lower p values. If we eliminate the 1.7-fold cut-
off, but maintain the p value <0.05, the CCM identified
493 genes, the ANOVA identified 499 genes, and the reg-
ularized t-test identified 729 differentially expressed genes
(Fig. 8B). Among these, 399 were in common between the
regularized t-test and ANOVA, 248 in common between
the CCM and the regularized t-test, and 188 in common
between the CCM and the ANOVA. These results demon-
strate that if the false-positive rate remains the same, the
regularized t-test is more sensitive than the traditional
ANOVA and has extensive overlap, while the CCM has the
least overlap between the other methods, but identifies
different genes with slightly less specificity.
In our analysis, we selected genes based on their p values
obtained from replicates of individual spots and did not
adjust these p-values for multiple comparisons. This may
be a major cause for the higher false positive rates for both
of our experimental designs. For the CCM, if we apply
Bonferroni correction, while we can eliminate all false
positives, we would also miss a majority of the
differentially expressed genes verified by Northern blot-
ting. Therefore, if accuracy is the main purpose of a study,
multiple comparison corrections should be used, while if
sensitivity is the main purpose, then it should not be used
with the understanding that the accuracy will be lower.
Comparison of a dye-swap versus a control correction 
method experimental design
For our experimental design, the dye-swap method had a
higher confirmation rate than the control correction
method. This is, in part, due to the smaller variance that
results from an effective doubling of the number of
treated samples in the dye-swap method compared to the
control correction method. Despite the higher degree of
accuracy, the dye-swap design identified fewer genes and
only detected down-regulated genes, whereas the control
correction identified 3-times the number of genes that
were both up- and down-regulated. However the control
correction method was less specific for up-regulated
genes. These differences may not solely reflect methodo-
logical differences, but likely result from experimental var-
iability produced by performing the experiments
X58141 Human mRNA for 
erythrocyte adducin alpha 
subunit
2.1 3.2E-2
AJ224442 Homo sapiens mRNA for 
putative methyltransferase
1.8 3.4E-3
X06661 Human mRNA for 27-kDa 
calbindin
2.1 9.0E-3
U24266 aldehyde dehydrogenase 4 
family, member A1
1.7 2.5E-3
U62432 Human nicotinic acetylcholine 
receptor alpha3 subunit 
precursor, mRNA, complete 
cds
1.8 7.0E-3
U79259 Human clone 23945 mRNA, 
complete cds
-1.7 4.2E-3
M18533 Homo sapiens dystrophin 
(DMD) mRNA, complete cds
-2.5 1.1E-2
J05401 Human sarcomeric 
mitochondrial creatine 
kinase(MtCK) gene, complete 
cds
2.2 1.5E-2
D13315 Human mRNA for lactoyl 
glutathione lyase
-1.7 4.6E-7
AB001740 Homo sapiens mRNA for p27 1.8 8.6E-4
M15661 Human ribosomal protein 
mRNA
-1.7 1.3E-4
Table 1: List of identified genes. Gene accession numbers, gene descriptions, fold-changes, and p-values for genes identified by the dye-
swap method with ANOVA and regularized t-test analysis and the control correction method (CCM). Genes are broadly classified into 
three groups: proliferation-related, differentiation-related and unclassified. (Continued)
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Northern blots confirm a majority of gene expression changes for both methodsFigur  7
Northern blots confirm a majority of gene expression changes for both methods. The far right-hand column shows northern 
blot results performed in triplicate for genes identified by each microarray design method. For each gene, the fold-change from 
the microarray together with the average fold-change quantified from the northern blots is shown. To correct for loading dif-
ferences, in the northern blots each measurement was normalized to the corresponding amount of 18S rRNA measured on 
each gel. A representative example of the 18S rRNA is shown on the bottom of the figure. Two of the Z74615 northern blot 
bands were discarded due to contamination. Down-regulated, up-regulated, and false positive genes that were not confirmed 
by northern blots are indicated.
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Summary of confirmation rates for the two methodsFigure 8
Summary of confirmation rates for the two methods. (A) A Venn diagram summarizes the number of genes identified by each 
experimental method using 1.7-fold and p < 0.05 cut-offs and the verification rate by northern blot. While all 5 genes common 
to both methods were confirmed, 7 out of 11 genes from control correction method were confirmed, and 6 out of 7 genes 
from the dye-swap method using the ANOVA were confirmed. 8 out of 9 genes identified with the regularized t-test were 
confirmed. (B) A Venn diagram summarizes the number of genes identified by each experimental method of p < 0.05 without a 
fold change restriction.
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independently on different days. Nonetheless, the results
presented here suggest that both methods have clear merit
in their abilities to show true gene expression changes,
particularly for expression changes of 2-fold or less, and
for genes with low signal intensities and/or low
abundance.
The final decision as to which method is preferred
depends on the experimental design. For example, the
amount of sample and number of replicates required are
important considerations both in terms of how difficult
the RNA is to obtain and the number of samples that need
to be compared. This also translates into the cost to per-
form the experiment. For instance, the dye-swap method
generates a larger sample size for the same number of
slides, thus producing greater significance when compar-
ing gene expression between two samples. However this
method requires a minimum of two slides and two differ-
ent labeling reactions per sample. If the amount of sample
is limited or population level replication is more desirable
than individual sample replication, the control correction
is more efficient since individual replicates for reverse dye
labeling are not required and each sample can be run with
only one slide. For example, to compare 6 treatment sam-
ples with a single control sample would require a mini-
mum of 12 microarrays using the dye-swap method,
whereas the minimum number of 8 arrays is possible
using the control correction method; 6 for treatment sam-
ples and 2 for controls.
Another common experimental design used for time
course or dose response studies is the reference design. In
fact, the control correction method described here is
essentially a modified reference design method where the
zero time or dose point is the control-control comparison.
As discussed above, using a very similar control sample to
correct the series will give less false positives and negatives
and a more accurate absolute value of the observed
change than a dissimilar, pooled reference sample.
Under-estimation of fold changes by cDNA microarrrays
Although our cDNA microarray results were accurate, the
measured changes generally underestimated the actual
changes measured by northern blots. Yuen et al. [6] simi-
larly found that both oligonucleotide arrays (GeneChips
by Affymetrix) and cDNA arrays underestimate fold
changes compared to quantitative RT-PCR. The cause for
this underestimation is not clear, however, it may be due
to the limited dynamic range of dye signal or non-specific
binding of the dye. Nonetheless, the limitations in accu-
racy and fold change estimation are far outweighed by the
ability of microarrays to identify biologically important
gene expression changes.
Conclusions
This study demonstrated that dye-swap and control cor-
rection experimental design paradigms for cDNA microar-
ray experiments are capable of detecting small,
biologically important changes in gene expression with
excellent fidelity while revealing important down-stream
anti-proliferative effects of neuregulin on breast epithelial
cells for future studies.
Methods
cDNA microarrays
Human cDNA glass microarrays, called the Alphamax
Genechip, were obtained from Alphagene Inc. (Woburn,
MA) containing 3333 cDNAs spotted in duplicate. The
cDNAs used are identical to commercially available
Micromax 2400 slides from Perkin Elmer Life Sciences
(Boston, MA), most of which were derived from a human
fetal brain cDNA library, with an additional 933 genes
(gene list available upon request).
MCF10AT cell culture – MCF10AT cells were from Dr.
Robert Pauley at the Karmanos Cancer Institute (Detroit,
MI). The cells were cultured in DMEM/F12 media (Invit-
rogen) supplemented with 5% horse serum (Invitrogen),
10 mM HEPES buffer (Invitrogen), 10 µg/ml insulin
(Sigma), 20 ng/ml EGF (Upstate Biotechnology), 100 ng/
ml cholera enterotoxin (CalBiochem) and 0.5 µg/ml
hydrocortisone (Sigma) at 37°C in 5% CO2 incubator.
Neuregulin treatment and RNA extraction – A recom-
binant human NRG β1 polypeptide (amino acids 14–
246) was generously provided by AMGEN (Thousand
Oaks, CA). After 3 days of culture, MCF10AT cells were
treated with human recombinant neuregulin β1 form for
24 hours. MCF10AT cells grown under similar conditions
without neuregulin treatment were used as a control. The
cells were then harvested and total RNA was extracted
using Ultraspec (Biotecx laboratories). The total RNA was
cleaned up by Rneasy kit (Qiagen) and quantified using a
fluorescent dye binding assay, Ribogreen (Molecular
Probes). RNA purity was assessed by agarose gel electro-
phoresis. Proliferation assays were performed by counting
quadruplicate cultures plated at 5000 cells/well using a
hemocytometer.
Microarray hybridization – cDNA microarrays were used
in a 2-step hybridization protocol that was optimized for
the Genisphere dendrimer labeling method. Total RNA
was reverse transcribed into cDNA containing a unique 5'
primer tag, using the Genisphere 3DNA expression array
detection kit. In brief, for each reaction, 3 µg of total RNA
was reverse transcribed using 0.2 µM oligo-dT-Genisphere
capture primer, 0.5 mM dNTP, 200 U Superscript II (Inv-
itrogen) in 1X first strand Superscript II buffer at 42°C for
2 h. The RNA from the DNA/RNA hybrids was denatured
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with 0.5 M NaOH / 50 mM EDTA at 65°C for 10 min. The
reaction was neutralized using 1 M Tris-HCl ph 7.5. The
contents of the tube containing the NRG-treated and
control cDNA were then mixed together and 3 µl linear
acrylamide (Ambion) and 250 µl of 3 M ammonium ace-
tate were added to them. cDNA was precipitated by add-
ing 100% Ethanol and incubating at -20°C for 30 min.
The cDNA was collected in a pellet by centrifugation at
13000 rpm for 15 min in a microcentrifuge. and resus-
pended in Alternate (formamide-containing) Hybridiza-
tion buffer (Genisphere) at 65°C for 10 min and
modified LNA blocker (Genisphere) with denatured Cot 1
DNA.
The entire mixture was added to the pre-hybridized array
(Alphamax) for hybridization at 55°C for at 36 hr. A clear
increase in signal was obtained with a 36 h hybridization
compared to 16 h. After hybridization, the arrays were
washed with 2X SSC and 0.2% SDS at 60°C for 15 min,
followed by a wash with 2X SSC and another with 0.2X
SSC at room temperature. For fluorescence detection, a
second hybridization with the dendrimer was optimal.
2.5 µl each of the Cy3 and Cy5 dendrimer in Hybridiza-
tion Buffer (Vial 6, Genisphere kit) were mixed with dena-
tured Cot1 DNA and differential expander and the
mixture was added to the pre-hybridized slides for hybrid-
ization at 60°C for 2 hrs. The slides were washed again as
described above.
Microarray data analysis method
Analysis of CCM experiment
Arrays were scanned with a GenePix 4000 A scanner
(Axon Instruments, Inc., Union City, CA). Images were
quantified using ImaGene Software (Biodiscovery, Inc.
Marina del Rey, CA) that uses a local background sub-
tracted from the signal. Signals not consistently detectable
(background corrected signal lower than 2 times of back-
ground standard deviation) were eliminated.
We fitted loess curve to the log transformed data using the
"loess" function in SAS software (SAS Institute Inc., NC)
for intensity dependent normalization followed by a t-test
to compare T/C with C/C ratio, gene by gene. The t-test
was performed on the normalized log ratio with Welch
correction for unequal variance. The control corrected
fold change was calculated as:
log (fold) = log(T/C)-log(C/C)
Analysis of dye-swap experiment
For the dye-swap method we performed the same back-
ground correction and data filtering for absent genes and
log transformations. We then used a two interconnect
ANOVA model [22,23] and Mixed Model Analysis of
Microarray Data (MANMADA) http://statgen.ncsu.edu/
ggibson/Manual.htm to identify differentially expressed
genes. First we use a normalization model for log-trans-
formed intensity measurements:
yij = µ + Ai + Dj + ADij + εij
Where µ is the sample mean, Ai is the effect of ith array, Dj
is the effect of dye cy3 or cy5, ADij is array dye interaction
and εij is random error. The residue from normalization
model is then used in following gene model to find treat-
ment effects on each gene:
rijkg = Aig + Djg + Tkg
Where rijkg is the residual of each gene from the normali-
zation model, Tkg is the treatment effect (control or
treated), and Aig and Djg are the array and dye effects,
respectively. The expression change for each gene is thus:
log (fold) = Ttreated-Tcontrol
Northern blots
5 µg total RNA isolated from MCF10AT cells was run on a
1.3% Agarose/2.2M Formaldehyde gel as described previ-
ously [31]. Probes were prepared by PCR from the same
clones used to spot the slides provided by Alphagene Inc
except for AJ224442, X86779 and U62739, where clones
BC011696, BI754516 and BG763631, with of over 99%
identity, were used as substitutes. Probes were generated
by random priming using PrimiT II kit (Stratagene) radi-
olabeled probes. The auto-radiographs within the linear
range of the film were scanned with a flatbed scanner with
transparency adapter and quantified using MetaMorph
(Universal Imaging) analysis software as described previ-
ously [32]. For time course measurements, the amount of
signal normalized for loading with either 18S RNA or
GAPDH were plotted together after first setting 100% to
the intensity of the control measurement at 48 hours and
setting the lowest intensity value to 0%.
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